AbbVie, Boehringer, Pfizer Drugs Face Generic Challengers: FDA
2014-12-03 20:25:56.624 GMT
By Catherine Larkin
Dec. 3 (Bloomberg) -- FDA posts recent generic-drug
applications with paragraph IV patent certification, meaning
generic cos. see brand-name patents as invalid or not infringed.
* Names of generic applicants aren’t disclosed
* Brand-name products listed:
* Boehringer’s Pradaxa eq. to 75mg base and 150mg base
* Novartis’s Durezol 0.05%
* Pfizer’s Nexium OTC 20mg
* AbbVie’s AndroGel 1.62% (1.25g and 2.5g packets)
* Afaxys’s ella 30mg
* Afaxys’s ella 30mg</li></ul>
FDA link: http://1.usa.gov/14y06yF
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Catherine Larkin in Chicago at +1-312-443-5968 or
clarkin4@bloomberg.net
To contact the editors responsible for this story:
Arie Shapira at +1-212-617-1488 or
ashapira3@bloomberg.net
Stefanie Batcho-Lino
2014-12-03 20:25:56.624 GMT
By Catherine Larkin
Dec. 3 (Bloomberg) -- FDA posts recent generic-drug
applications with paragraph IV patent certification, meaning
generic cos. see brand-name patents as invalid or not infringed.
* Names of generic applicants aren’t disclosed
* Brand-name products listed:
* Boehringer’s Pradaxa eq. to 75mg base and 150mg base
* Novartis’s Durezol 0.05%
* Pfizer’s Nexium OTC 20mg
* AbbVie’s AndroGel 1.62% (1.25g and 2.5g packets)
* Afaxys’s ella 30mg
* Afaxys’s ella 30mg</li></ul>
FDA link: http://1.usa.gov/14y06yF
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Catherine Larkin in Chicago at +1-312-443-5968 or
clarkin4@bloomberg.net
To contact the editors responsible for this story:
Arie Shapira at +1-212-617-1488 or
ashapira3@bloomberg.net
Stefanie Batcho-Lino